gene a,gene b,synonym a,synonym b,cell line,phenotype,additional notes,interaction
KRAS,PIK3CA,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,CLOVE|CWS5|MCAP|MCM|MCMTC|PI3K|p110-alpha,HCT-116 cell,viability|Growth abnormality,5% FDR|CRISPR-Cas9 library genetic interaction screen|GIST: A-phenotypic negative genetic interaction|TKO (Toronto KnockOut) library,synthetic lethality
KRAS,RAF1,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,CMD1NN|CRAF|NS5|Raf-1|c-Raf,HCT-116 cell,viability|Growth abnormality,5% FDR|CRISPR-Cas9 library genetic interaction screen|GIST: A-phenotypic negative genetic interaction|TKO (Toronto KnockOut) library,synthetic lethality
KRAS,MAPK1,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,ERK|ERK-2|ERK2|ERT1|MAPK2|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,HCT-116 cell,Growth abnormality|viability,5% FDR|CRISPR-Cas9 library genetic interaction screen|GIST: A-phenotypic negative genetic interaction|TKO (Toronto KnockOut) library,synthetic lethality
BRAF,MAPK1,B-RAF1|BRAF1|NS7|RAFB1,ERK|ERK-2|ERK2|ERT1|MAPK2|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,A-375 cell,viability|Growth abnormality,5% FDR|CRISPR-Cas9 library genetic interaction screen|GIST: A-phenotypic negative genetic interaction|TKO (Toronto KnockOut) library,synthetic lethality
KRAS,RCE1,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,FACE2|RCE1A|RCE1B,Ras oncogenic mutant cell lines,viability|Growth abnormality,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
KRAS,ICMT,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,HSTE14|MST098|MSTP098|PCCMT|PCMT|PPMT,Ras oncogenic mutant cell lines,viability|Growth abnormality,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
KRAS,RAF1,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,CMD1NN|CRAF|NS5|Raf-1|c-Raf,Ras oncogenic mutant cell lines,viability|Growth abnormality,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
KRAS,SHOC2,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,SIAA0862|SOC2|SUR8,Ras oncogenic mutant cell lines,viability|Growth abnormality,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
KRAS,PREX1,C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|KI-RAS|KRAS1|KRAS2|NS|NS3|RASK2,P-REX1,Ras oncogenic mutant cell lines,viability|Growth abnormality,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
NRAS,RCE1,ALPS4|CMNS|N-ras|NCMS|NRAS1|NS6,FACE2|RCE1A|RCE1B,Ras oncogenic mutant cell lines,Growth abnormality|viability,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
NRAS,ICMT,ALPS4|CMNS|N-ras|NCMS|NRAS1|NS6,HSTE14|MST098|MSTP098|PCCMT|PCMT|PPMT,Ras oncogenic mutant cell lines,Growth abnormality|viability,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
NRAS,RAF1,ALPS4|CMNS|N-ras|NCMS|NRAS1|NS6,CMD1NN|CRAF|NS5|Raf-1|c-Raf,Ras oncogenic mutant cell lines,Growth abnormality|viability,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
NRAS,SHOC2,ALPS4|CMNS|N-ras|NCMS|NRAS1|NS6,SIAA0862|SOC2|SUR8,Ras oncogenic mutant cell lines,Growth abnormality|viability,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
NRAS,PREX1,ALPS4|CMNS|N-ras|NCMS|NRAS1|NS6,P-REX1,Ras oncogenic mutant cell lines,Growth abnormality|viability,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines (KRAS and NRAS)|Negative genetic,synthetic lethality
NRAS,GOLGA7,ALPS4|CMNS|N-ras|NCMS|NRAS1|NS6,GCP16|GOLGA3AP1|GOLGA7A|HSPC041,Ras oncogenic mutant cell lines,viability|Growth abnormality,CRISPR|Hit genes show differential essentiality in Ras oncogenic mutant cell lines-NRAS|Negative genetic,synthetic lethality
HSP90AA1,LLGL1,EL52|HSP86|HSP89A|HSP90A|HSP90N|HSPC1|HSPCA|HSPCAL1|HSPCAL4|HSPN|Hsp89|Hsp90|LAP-2|LAP2,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug AUY922|HeLa cervical cancer cell line,synthetic lethality
HSP90AA1,RB1,EL52|HSP86|HSP89A|HSP90A|HSP90N|HSPC1|HSPCA|HSPCAL1|HSPCAL4|HSPN|Hsp89|Hsp90|LAP-2|LAP2,OSRC|PPP1R130|RB|p105-Rb|pRb|pp110,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug AUY922|HeLa cervical cancer cell line,synthetic lethality
HSP90AA1,FZR1,EL52|HSP86|HSP89A|HSP90A|HSP90N|HSPC1|HSPCA|HSPCAL1|HSPCAL4|HSPN|Hsp89|Hsp90|LAP-2|LAP2,CDC20C|CDH1|FZR|FZR2|HCDH|HCDH1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug AUY922|HeLa cervical cancer cell line,synthetic lethality
HSP90AA1,MCL1,EL52|HSP86|HSP89A|HSP90A|HSP90N|HSPC1|HSPCA|HSPCAL1|HSPCAL4|HSPN|Hsp89|Hsp90|LAP-2|LAP2,BCL2L3|EAT|MCL1-ES|MCL1L|MCL1S|Mcl-1|TM|bcl2-L-3|mcl1/EAT,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug AUY922|HeLa cervical cancer cell line,synthetic lethality
HSP90AA1,CDKN1B,EL52|HSP86|HSP89A|HSP90A|HSP90N|HSPC1|HSPCA|HSPCAL1|HSPCAL4|HSPN|Hsp89|Hsp90|LAP-2|LAP2,CDKN4|KIP1|MEN1B|MEN4|P27KIP1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug AUY922|HeLa cervical cancer cell line,synthetic lethality
HSP90AA1,ATR,EL52|HSP86|HSP89A|HSP90A|HSP90N|HSPC1|HSPCA|HSPCAL1|HSPCAL4|HSPN|Hsp89|Hsp90|LAP-2|LAP2,FCTCS|FRP1|MEC1|SCKL|SCKL1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug AUY922|HeLa cervical cancer cell line,synthetic lethality
CHEK2,WEE1,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,WEE1A|WEE1hu,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,CHEK1,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,CHK1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,CDC6,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,CDC18L|HsCDC18|HsCDC6,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,CDC73,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,BLM,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,RFC1,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,A1|MHCBFB|PO-GA|RECC1|RFC|RFC140,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,RAD17,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,CCYC|HRAD17|R24L|RAD17SP|RAD24,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,FZR1,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,CDC20C|CDH1|FZR|FZR2|HCDH|HCDH1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,ATAD5,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,LLGL1,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,CDC14A,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,cdc14|hCDC14,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,RPS10,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,DBA9|S10,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,WRN,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,RECQ3|RECQL2|RECQL3,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,ATR,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,FCTCS|FRP1|MEC1|SCKL|SCKL1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,DAAM1,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,-,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,TTN,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK2,BRD4,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,CAP|HUNK1|HUNKI|MCAP,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,WEE1,CHK1,WEE1A|WEE1hu,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,CDC6,CHK1,CDC18L|HsCDC18|HsCDC6,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,CDC73,CHK1,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|Drug: MK-8776|HeLa cervical cancer cell line",synthetic lethality
CHEK1,BLM,CHK1,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|Drug: MK-8776|HeLa cervical cancer cell line",synthetic lethality
CHEK1,RFC1,CHK1,A1|MHCBFB|PO-GA|RECC1|RFC|RFC140,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,RAD17,CHK1,CCYC|HRAD17|R24L|RAD17SP|RAD24,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,FZR1,CHK1,CDC20C|CDH1|FZR|FZR2|HCDH|HCDH1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,ATAD5,CHK1,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,LLGL1,CHK1,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,CDC14A,CHK1,cdc14|hCDC14,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|Drug: MK-8776|HeLa cervical cancer cell line",synthetic lethality
CHEK1,RPS10,CHK1,DBA9|S10,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,WRN,CHK1,RECQ3|RECQL2|RECQL3,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|Drug: MK-8776|HeLa cervical cancer cell line",synthetic lethality
CHEK1,ATR,CHK1,FCTCS|FRP1|MEC1|SCKL|SCKL1,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,DAAM1,CHK1,-,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,TTN,CHK1,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|HeLa cervical cancer cell line",synthetic lethality
CHEK1,BRD4,CHK1,CAP|HUNK1|HUNKI|MCAP,HeLa cell,Growth abnormality,"CHEK1,CHEK2 double mutant as drug target|Chemo-genetic screen with siRNAs|Drug AZD7762|Drug: MK-8776|HeLa cervical cancer cell line",synthetic lethality
CSNK2A1,APC,CK2A1|CKII|CSNK2A3,BTPS2|DP2|DP2.5|DP3|GS|PPP1R46,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Casein Kinase II Inhibitor III|HeLa cervical cancer cell line,synthetic lethality
CSNK2A1,ATAD5,CK2A1|CKII|CSNK2A3,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Casein Kinase II Inhibitor III|HeLa cervical cancer cell line,synthetic lethality
CSNK2A1,STK11,CK2A1|CKII|CSNK2A3,LKB1|PJS|hLKB1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Casein Kinase II Inhibitor III|HeLa cervical cancer cell line,synthetic lethality
ALDH2,RPL11,ALDH-E2|ALDHI|ALDM,DBA7|GIG34|L11,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
ALDH2,ARID1A,ALDH-E2|ALDHI|ALDM,B120|BAF250|BAF250a|BM029|C1orf4|ELD|MRD14|OSA1|P270|SMARCF1|hELD|hOSA1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
ALDH2,XRCC3,ALDH-E2|ALDHI|ALDM,CMM6,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
ALDH2,ATAD5,ALDH-E2|ALDHI|ALDM,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
ALDH2,APC,ALDH-E2|ALDHI|ALDM,BTPS2|DP2|DP2.5|DP3|GS|PPP1R46,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
ALDH2,PHB2,ALDH-E2|ALDHI|ALDM,BAP|BCAP37|Bap37|PNAS-141|REA|p22,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
ALDH2,RAD23B,ALDH-E2|ALDHI|ALDM,HHR23B|HR23B|P58,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Disulfiram|HeLa cervical cancer cell line,synthetic lethality
MTOR,CHEK1,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,CHK1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Everolimus|HeLa cervical cancer cell line,synthetic lethality
MTOR,YWHAZ,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,14-3-3-zeta|HEL-S-3|HEL4|KCIP-1|YWHAD,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Everolimus|HeLa cervical cancer cell line,synthetic lethality
ADA,WEE1,-,WEE1A|WEE1hu,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: fludarabine|HeLa cervical cancer cell line,synthetic lethality
ADA,CHEK1,-,CHK1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: fludarabine|HeLa cervical cancer cell line,synthetic lethality
ADA,BLM,-,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: fludarabine|HeLa cervical cancer cell line,synthetic lethality
TOP1,CHEK1,TOPI,CHK1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,BRCA2,TOPI,BRCC2|BROVCA2|FACD|FAD|FAD1|FANCD|FANCD1|GLM3|PNCA2|XRCC11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,WEE1,TOPI,WEE1A|WEE1hu,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,PALB2,TOPI,FANCN|PNCA3,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,RAD17,TOPI,CCYC|HRAD17|R24L|RAD17SP|RAD24,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,LLGL1,TOPI,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,MSH2,TOPI,COCA1|FCC1|HNPCC|HNPCC1|LCFS2,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,NF1,TOPI,NFNS|VRNF|WSS,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,RPS11,TOPI,S11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,CDC73,TOPI,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,CDC6,TOPI,CDC18L|HsCDC18|HsCDC6,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,MAP3K4,TOPI,MAPKKK4|MEKK 4|MEKK4|MTK1|PRO0412,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,TTN,TOPI,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP1,FH,TOPI,HLRCC|LRCC|MCL|MCUL1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,CHEK1,TOP2|TP2A,CHK1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,BRCA2,TOP2|TP2A,BRCC2|BROVCA2|FACD|FAD|FAD1|FANCD|FANCD1|GLM3|PNCA2|XRCC11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,WEE1,TOP2|TP2A,WEE1A|WEE1hu,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,PALB2,TOP2|TP2A,FANCN|PNCA3,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,RAD17,TOP2|TP2A,CCYC|HRAD17|R24L|RAD17SP|RAD24,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,LLGL1,TOP2|TP2A,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,MSH2,TOP2|TP2A,COCA1|FCC1|HNPCC|HNPCC1|LCFS2,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,NF1,TOP2|TP2A,NFNS|VRNF|WSS,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,RPS11,TOP2|TP2A,S11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,CDC73,TOP2|TP2A,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,CDC6,TOP2|TP2A,CDC18L|HsCDC18|HsCDC6,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,MAP3K4,TOP2|TP2A,MAPKKK4|MEKK 4|MEKK4|MTK1|PRO0412,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,TTN,TOP2|TP2A,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP2A,FH,TOP2|TP2A,HLRCC|LRCC|MCL|MCUL1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,CHEK1,TOP3|ZGRF7,CHK1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,BRCA2,TOP3|ZGRF7,BRCC2|BROVCA2|FACD|FAD|FAD1|FANCD|FANCD1|GLM3|PNCA2|XRCC11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,WEE1,TOP3|ZGRF7,WEE1A|WEE1hu,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,PALB2,TOP3|ZGRF7,FANCN|PNCA3,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,RAD17,TOP3|ZGRF7,CCYC|HRAD17|R24L|RAD17SP|RAD24,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,LLGL1,TOP3|ZGRF7,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,MSH2,TOP3|ZGRF7,COCA1|FCC1|HNPCC|HNPCC1|LCFS2,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,NF1,TOP3|ZGRF7,NFNS|VRNF|WSS,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,RPS11,TOP3|ZGRF7,S11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,CDC73,TOP3|ZGRF7,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,CDC6,TOP3|ZGRF7,CDC18L|HsCDC18|HsCDC6,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,MAP3K4,TOP3|ZGRF7,MAPKKK4|MEKK 4|MEKK4|MTK1|PRO0412,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,TTN,TOP3|ZGRF7,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
TOP3A,FH,TOP3|ZGRF7,HLRCC|LRCC|MCL|MCUL1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: TOP1,TOP2A,TOP3A triple mutant|Drug: irinotecan|HeLa cervical cancer cell line",synthetic lethality
DHFR,CDC73,DHFRP1|DYR,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: methotrexate|HeLa cervical cancer cell line,synthetic lethality
DHFR,CHEK1,DHFRP1|DYR,CHK1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: methotrexate|HeLa cervical cancer cell line,synthetic lethality
DHFR,WEE1,DHFRP1|DYR,WEE1A|WEE1hu,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: methotrexate|HeLa cervical cancer cell line,synthetic lethality
WEE1,CHEK1,WEE1A|WEE1hu,CHK1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,CDC73,WEE1A|WEE1hu,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,TTN,WEE1A|WEE1hu,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,RB1,WEE1A|WEE1hu,OSRC|PPP1R130|RB|p105-Rb|pRb|pp110,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,ING4,WEE1A|WEE1hu,p29ING4,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,FZR1,WEE1A|WEE1hu,CDC20C|CDH1|FZR|FZR2|HCDH|HCDH1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,WRN,WEE1A|WEE1hu,RECQ3|RECQL2|RECQL3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,BLM,WEE1A|WEE1hu,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,ATAD5,WEE1A|WEE1hu,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,BRD4,WEE1A|WEE1hu,CAP|HUNK1|HUNKI|MCAP,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,FH,WEE1A|WEE1hu,HLRCC|LRCC|MCL|MCUL1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,WEE1,WEE1A|WEE1hu,WEE1A|WEE1hu,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,CDKN1B,WEE1A|WEE1hu,CDKN4|KIP1|MEN1B|MEN4|P27KIP1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,XRCC3,WEE1A|WEE1hu,CMM6,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,CDK12,WEE1A|WEE1hu,CRK7|CRKR|CRKRS,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
WEE1,CDC6,WEE1A|WEE1hu,CDC18L|HsCDC18|HsCDC6,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
CHEK1,MTOR,CHK1,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-8776|HeLa cervical cancer cell line,synthetic lethality
CHEK1,SMARCC1,CHK1,BAF155|CRACC1|Rsc8|SRG3|SWI3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-8776|HeLa cervical cancer cell line,synthetic lethality
CHEK1,TUSC3,CHK1,D8S1992|M33|MRT22|MRT7|N33|OST3A,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-8776|HeLa cervical cancer cell line,synthetic lethality
CHEK1,TCEA1,CHK1,GTF2S|SII|TCEA|TF2S|TFIIS,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-8776|HeLa cervical cancer cell line,synthetic lethality
CHEK1,FHIT,CHK1,AP3Aase|FRA3B,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-8776|HeLa cervical cancer cell line,synthetic lethality
CHEK1,USP11,CHK1,UHX1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-8776|HeLa cervical cancer cell line,synthetic lethality
IMPDH1,CHEK1,IMPD|IMPD1|LCA11|RP10|sWSS2608,CHK1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MMF|HeLa cervical cancer cell line,synthetic lethality
IMPDH1,WEE1,IMPD|IMPD1|LCA11|RP10|sWSS2608,WEE1A|WEE1hu,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MMF|HeLa cervical cancer cell line,synthetic lethality
IMPDH1,RPS11,IMPD|IMPD1|LCA11|RP10|sWSS2608,S11,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MMF|HeLa cervical cancer cell line,synthetic lethality
IMPDH1,CDC73,IMPD|IMPD1|LCA11|RP10|sWSS2608,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MMF|HeLa cervical cancer cell line,synthetic lethality
IMPDH1,SH3GL1,IMPD|IMPD1|LCA11|RP10|sWSS2608,CNSA1|EEN|SH3D2B|SH3P8,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MMF|HeLa cervical cancer cell line,synthetic lethality
PARP1,BRCA2,ADPRT|ADPRT 1|ADPRT1|ARTD1|PARP|PARP-1|PPOL|pADPRT-1,BRCC2|BROVCA2|FACD|FAD|FAD1|FANCD|FANCD1|GLM3|PNCA2|XRCC11,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Olaparib|HeLa cervical cancer cell line,synthetic lethality
PARP1,BRCA1,ADPRT|ADPRT 1|ADPRT1|ARTD1|PARP|PARP-1|PPOL|pADPRT-1,BRCAI|BRCC1|BROVCA1|FANCS|IRIS|PNCA4|PPP1R53|PSCP|RNF53,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: Olaparib|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,TUSC3,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,D8S1992|M33|MRT22|MRT7|N33|OST3A,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD0325901|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,MTOR,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD0325901|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,TTN,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD0325901|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,FH,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,HLRCC|LRCC|MCL|MCUL1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD0325901|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,ING5,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,p28ING5,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD0325901|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,BLM,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD0325901|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,ATAD5,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD98059|HeLa cervical cancer cell line,synthetic lethality
MAP2K1,STK11,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,LKB1|PJS|hLKB1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: PD98059|HeLa cervical cancer cell line,synthetic lethality
CDC7,BRD4,CDC7L1|HsCDC7|Hsk1|huCDC7,CAP|HUNK1|HUNKI|MCAP,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: CDC7,CDK9 double mutant|Drug: PHA-767491|HeLa cervical cancer cell line",synthetic lethality
CDC7,RPS11,CDC7L1|HsCDC7|Hsk1|huCDC7,S11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: CDC7,CDK9 double mutant|Drug: PHA-767491|HeLa cervical cancer cell line",synthetic lethality
CDC7,ING5,CDC7L1|HsCDC7|Hsk1|huCDC7,p28ING5,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: CDC7,CDK9 double mutant|Drug: PHA-767491|HeLa cervical cancer cell line",synthetic lethality
CDK9,BRD4,C-2k|CDC2L4|CTK1|PITALRE|TAK,CAP|HUNK1|HUNKI|MCAP,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: CDC7,CDK9 double mutant|Drug: PHA-767491|HeLa cervical cancer cell line",synthetic lethality
CDK9,RPS11,C-2k|CDC2L4|CTK1|PITALRE|TAK,S11,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: CDC7,CDK9 double mutant|Drug: PHA-767491|HeLa cervical cancer cell line",synthetic lethality
CDK9,ING5,C-2k|CDC2L4|CTK1|PITALRE|TAK,p28ING5,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: CDC7,CDK9 double mutant|Drug: PHA-767491|HeLa cervical cancer cell line",synthetic lethality
MAPK1,FH,ERK|ERK-2|ERK2|ERT1|MAPK2|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,HLRCC|LRCC|MCL|MCUL1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: SCH772984|HeLa cervical cancer cell line,synthetic lethality
MAPK1,TTN,ERK|ERK-2|ERK2|ERT1|MAPK2|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: SCH772984|HeLa cervical cancer cell line,synthetic lethality
MAPK1,MTOR,ERK|ERK-2|ERK2|ERT1|MAPK2|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: SCH772984|HeLa cervical cancer cell line,synthetic lethality
MAPK1,RPS11,ERK|ERK-2|ERK2|ERT1|MAPK2|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,S11,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: SCH772984|HeLa cervical cancer cell line,synthetic lethality
RABGGTB,XRCC3,GGTB,CMM6,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
RABGGTB,ATAD5,GGTB,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
RABGGTB,BLM,GGTB,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
RABGGTB,MTOR,GGTB,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
RABGGTB,RPS19,GGTB,DBA|DBA1|S19,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
FNTA,XRCC3,FPTA|PGGT1A|PTAR2,CMM6,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
FNTA,ATAD5,FPTA|PGGT1A|PTAR2,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
FNTA,BLM,FPTA|PGGT1A|PTAR2,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
FNTA,MTOR,FPTA|PGGT1A|PTAR2,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
FNTA,RPS19,FPTA|PGGT1A|PTAR2,DBA|DBA1|S19,HeLa cell,Growth abnormality,"Chemo-genetic screen with siRNAs|Drug target: RABGGTB,FNTA double mutant|Drug: tipifarnib|HeLa cervical cancer cell line",synthetic lethality
TUBA1A,TUSC3,B-ALPHA-1|LIS3|TUBA3,D8S1992|M33|MRT22|MRT7|N33|OST3A,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,CDC73,B-ALPHA-1|LIS3|TUBA3,C1orf28|FIHP|HPTJT|HRPT1|HRPT2|HYX,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,ATAD5,B-ALPHA-1|LIS3|TUBA3,C17orf41|ELG1|FRAG1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,CHEK1,B-ALPHA-1|LIS3|TUBA3,CHK1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,LLGL1,B-ALPHA-1|LIS3|TUBA3,DLG4|HUGL|HUGL-1|HUGL1|LLGL,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,ING4,B-ALPHA-1|LIS3|TUBA3,p29ING4,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,ING5,B-ALPHA-1|LIS3|TUBA3,p28ING5,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,WRN,B-ALPHA-1|LIS3|TUBA3,RECQ3|RECQL2|RECQL3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,BLM,B-ALPHA-1|LIS3|TUBA3,BS|RECQ2|RECQL2|RECQL3,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,XRCC3,B-ALPHA-1|LIS3|TUBA3,CMM6,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,RB1,B-ALPHA-1|LIS3|TUBA3,OSRC|PPP1R130|RB|p105-Rb|pRb|pp110,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,YWHAZ,B-ALPHA-1|LIS3|TUBA3,14-3-3-zeta|HEL-S-3|HEL4|KCIP-1|YWHAD,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,WEE1,B-ALPHA-1|LIS3|TUBA3,WEE1A|WEE1hu,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,RPL11,B-ALPHA-1|LIS3|TUBA3,DBA7|GIG34|L11,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,TTN,B-ALPHA-1|LIS3|TUBA3,CMD1G|CMH9|CMPD4|EOMFC|HMERF|LGMD2J|MYLK5|TMD,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,PHB2,B-ALPHA-1|LIS3|TUBA3,BAP|BCAP37|Bap37|PNAS-141|REA|p22,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,CDC14A,B-ALPHA-1|LIS3|TUBA3,cdc14|hCDC14,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,MTOR,B-ALPHA-1|LIS3|TUBA3,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
TUBA1A,CHEK2,B-ALPHA-1|LIS3|TUBA3,CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: vinorelbine|HeLa cervical cancer cell line,synthetic lethality
WEE1,MTOR,WEE1A|WEE1hu,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,HeLa cell,Growth abnormality,Chemo-genetic screen with siRNAs|Drug: MK-1775|HeLa cervical cancer cell line,synthetic lethality
BRAF,MAP2K1,B-RAF1|BRAF1|NS7|RAFB1,CFC3|MAPKK1|MEK1|MKK1|PRKMK1,A-375 cell,viability|Growth abnormality,5% FDR|CRISPR-Cas9 library genetic interaction screen|GIST: A-phenotypic negative genetic interaction|TKO (Toronto KnockOut) library,synthetic lethality
CSK,SLC3A2,-,4F2|4F2HC|4T2HC|CD98|CD98HC|MDU1|NACAE,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RGSL1,-,RGSL|RGSL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NUPL1,-,PRO2463,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CEP290,-,3H11Ag|BBS14|CT87|JBTS5|LCA10|MKS4|NPHP6|POC3|SLSN6|rd16,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DDX60,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARHGAP10,-,GRAF2|PS-GAP|PSGAP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATP11B,-,ATPIF|ATPIR,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARL14,-,ARF7,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PAH,-,PH|PKU|PKU1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLCZ1,-,NYD-SP27|PLC-zeta-1|PLCzeta,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF224,-,BMZF-2|BMZF2|KOX22|ZNF255|ZNF27,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NME7,-,CFAP67|MN23H7|NDK 7|NDK7|nm23-H7,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MICU1,-,CALC|CBARA1|EFHA3|MPXPS,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GIPC2,-,SEMCAP-2|SEMCAP2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CYLD,-,BRSS|CDMT|CYLD1|CYLDI|EAC|MFT|MFT1|SBS|TEM|USPL2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXW12,-,FBW12|FBXO12|FBXO35,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GNB4,-,CMTD1F,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KDM6A,-,KABUK2|UTX|bA386N14.2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PKHD1L1,-,PKHDL1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NDUFA6,-,B14|CI-B14|LYRM6|NADHB14,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC172,-,C10orf96,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM184C,-,TMEM34,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GOLT1A,-,CGI-141|GOT1|HMFN1187|YMR292W,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ABRACL,-,C6orf115|Costars|HSPC280|PRO2013,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SGIP1,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KLHL8,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TROVE2,-,RO60|RORNP|SSA2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SCIN,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC30A5,-,ZNT5|ZNTL1|ZTL1|ZnT-5,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PFKFB2,-,PFK-2/FBPase-2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MTM1,-,CNM|MTMX|XLMTM,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PIBF1,-,C13orf24|CEP90|PIBF,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MTMR2,-,CMT4B|CMT4B1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,YWHAQ,-,14-3-3|1C5|HS1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SULT1B1,-,ST1B1|ST1B2|SULT1B2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DCAF17,-,C2orf37,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERMAP,-,BTN5|PRO2801|RD|SC,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MAGIX,-,JM10|PDZX,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TC2N,-,C14orf47|C2CD1|MTAC2D1|Tac2-N,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SYCP1,-,CT8|HOM-TES-14|SCP-1|SCP1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FNDC3B,-,FAD104|PRO4979|YVTM2421,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NDUFV2,-,CI-24k,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC30,-,PFD6L|PFDN6L,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GAB1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GXYLT1,-,GLT8D3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DLG2,-,PPP1R58|PSD-93|PSD93|chapsyn-110,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C10orf131,-,bA690P14.3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NCR2,-,CD336|LY95|NK-p44|NKP44|dJ149M18.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SEMA3D,-,Sema-Z2|coll-2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MRS2,-,HPT|MRS2L,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LMLN,-,GP63|INV|IX14|MSP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GRHL2,-,BOM|DFNA28|ECTDS|TFCP2L3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GABRA4,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UBXN7,-,UBXD7,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TLE1,-,ESG|ESG1|GRG1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AKT1,-,AKT|CWS6|PKB|PKB-ALPHA|PRKBA|RAC|RAC-ALPHA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SPATA22,-,NYD-SP20|NYDSP20,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GATA3,-,HDR|HDRS,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MSH3,-,DUP|MRP1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,OGN,-,OG|OIF|SLRR3A,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HADHB,-,ECHB|MTPB|TP-BETA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LAMB3,-,BM600-125KDA|LAM5|LAMNB1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KBTBD4,-,BKLHD4|HSPC252,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MCM8,-,C20orf154|dJ967N21.5,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC90B,-,MDS011|MDS025,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NAF1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MLLT11,-,AF1Q,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARHGEF12,-,LARG|PRO2792,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FETUB,-,16G2|Gugu|IRL685,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NEK5,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PROCA1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANO5,-,GDD1|LGMD2L|TMEM16E,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C9orf43,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TNIP3,-,ABIN-3|LIND,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CAMK1,-,CAMKI,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC25A16,-,D10S105E|GDA|GDC|HGT.1|ML7|hML7,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CKAP2L,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERBB2,-,CD340|HER-2|HER-2/neu|HER2|MLN 19|NEU|NGL|TKR1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PUS10,-,CCDC139|DOBI,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IAPP,-,DAP|IAP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLEKHD1,-,UPF0639,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,INA,-,NEF5|NF-66|TXBP-1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CFI,-,AHUS3|ARMD13|C3BINA|C3b-INA|FI|IF|KAF,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM71D,-,C14orf54,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,COX19,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MRPS9,-,MRP-S9|RPMS9|S9mt,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ALKBH3,-,ABH3|DEPC-1|DEPC1|PCA1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C11orf49,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM108,-,CT124,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NAGPA,-,APAA|UCE,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRCH3,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GRSF1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,XPNPEP3,-,APP3|NPHPL1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERGIC2,-,Erv41|PTX1|cd002,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATP1A4,-,ATP1A1|ATP1AL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLXDC1,-,TEM3|TEM7,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EPB41L4A,-,EPB41L4|NBL4,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FCHSD2,-,NWK|SH3MD3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EPYC,-,DSPG3|PGLB|Pg-Lb|SLRR3B,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF415,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HECW2,-,NEDL2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DAO,-,DAAO|DAMOX|OXDA,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMX4,-,DJ971N18.2|PDIA14|TXNDC13,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF214,-,BAZ-1|BAZ1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UGP2,-,UDPG|UDPGP|UDPGP2|UGP1|UGPP1|UGPP2|pHC379,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SNX2,-,TRG-9,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CUL5,-,VACM-1|VACM1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IL21,-,CVID11|IL-21|Za11,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERN2,-,IRE1-BETA|IRE1b,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FANCL,-,FAAP43|PHF9|POG,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RBAK,-,ZNF769,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LIPI,-,CT17|LPDL|PLA1C|mPA-PLA1 beta,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EFCAB7,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PKD1,-,PBP|Pc-1|TRPP1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CACUL1,-,C10orf46|CAC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PNMAL1,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,OPALIN,-,HTMP10|TMEM10|TMP10,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PTPRZ1,-,HPTPZ|HPTPzeta|PTP-ZETA|PTP18|PTPRZ|PTPZ|R-PTP-zeta-2|RPTPB|RPTPbeta|phosphacan,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TARBP1,-,TRM3|TRP-185|TRP185,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CTSE,-,CATE,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATAD2,-,ANCCA|CT137|PRO2000,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SCG3,-,SGIII,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UBL7,-,BMSC-UbP|TCBA1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC6,-,D10S170|H4|PTC|TPC|TST1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPP1R36,-,C14orf50,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LIMS1,-,PINCH|PINCH-1|PINCH1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHIC2,-,BTL,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPP2R5B,-,B56B|PR61B,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TEDDM1,-,EDDM9|Epdd1|HE9|TMEM45C,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C1orf21,-,PIG13,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CNTRL,-,CEP1|CEP110|FAN|bA165P4.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STARD9,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STAM,-,STAM-1|STAM1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARMC1,-,Arcp,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RAG2,-,RAG-2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AVL9,-,KIAA0241,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RALGAPA2,-,AS250|C20orf74|bA287B20.1|dJ1049G11|dJ1049G11.4|p220,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ALDH6A1,-,MMSADHA|MMSDH,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLEKHG4,-,ARHGEF44|PRTPHN1|SCA4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RALGPS1,-,RALGEF2|RALGPS1A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MIA2,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C1orf185,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GFRA3,-,GDNFR3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CETN2,-,CALT|CEN2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KIAA1143,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATF6,-,ATF6A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PYROXD2,-,C10orf33|FP3420,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UPRT,-,FUR1|UPP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CRYGS,-,CRYG8|CTRCT20,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TCEANC,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARRDC1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CYTH3,-,ARNO3|GRP1|PSCD3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IL6,-,BSF2|HGF|HSF|IFNB2|IL-6,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,THBS3,-,TSP3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BBS2,-,BBS,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHIA,-,AMCASE|CHIT2|TSA1902,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CXCL10,-,C7|IFI10|INP10|IP-10|SCYB10|crg-2|gIP-10|mob-1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BAG5,-,BAG-5,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXO8,-,FBS|FBX8,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HMMR,-,CD168|IHABP|RHAMM,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HYDIN,-,CILD5|HYDIN1|HYDIN2|PPP1R31,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,POU2F1,-,OCT1|OTF1|oct-1B,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXL2,-,FBL2|FBL3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EPHB2,-,CAPB|DRT|EK5|EPHT3|ERK|Hek5|PCBC|Tyro5,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IFT43,-,C14orf179|CED3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IFT52,-,C20orf9|CGI-53|NGD2|NGD5|dJ1028D15.1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CD300LF,-,CD300f|CLM-1|CLM1|IREM-1|IREM1|IgSF13|LMIR3|NKIR,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF639,-,6230400O18Rik|ANC-2H01|ANC_2H01|ZASC1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,USP6NL,-,RNTRE|TRE2NL|USP6NL-IT1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CMYA5,-,C5orf10|SPRYD2|TRIM76,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CFTR,-,ABC35|ABCC7|CF|CFTR/MRP|MRP7|TNR-CFTR|dJ760C5.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM233,-,DSPB2|IFITMD2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EGR2,-,AT591|CMT1D|CMT4E|KROX20,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TAPT1,-,CMVFR,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,THAP2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STX6,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CPEB2,-,CPE-BP2|CPEB-2|hCPEB-2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZCCHC11,-,PAPD3|TUT4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DPM2,-,CDG1U,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATXN1L,-,BOAT|BOAT1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KCTD3,-,NY-REN-45,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RNF125,-,TRAC-1|TRAC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PANK2,-,C20orf48|HARP|HSS|NBIA1|PKAN,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CLECL1,-,DCAL-1|DCAL1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SNX16,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZMYM2,-,FIM|MYM|RAMP|SCLL|ZNF198,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IL1RL2,-,IL-1Rrp2|IL-36R|IL1R-rp2|IL1RRP2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PRKAG1,-,AMPKG,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CAPN3,-,CANP3|CANPL3|LGMD2|LGMD2A|nCL-1|p94,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC25A21,-,ODC|ODC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GABRA2,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC129,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HORMAD2,-,CT46.2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,METAP1D,-,MAP 1D|MAP1D|MetAP 1D|Metap1l,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC26A2,-,D5S1708|DTD|DTDST|EDM4|MST153|MSTP157,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,POU1F1,-,CPHD1|GHF-1|PIT1|POU1F1a|Pit-1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MFN1,-,hfzo1|hfzo2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HSF2,-,HSF 2|HSTF 2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NRD1,-,hNRD1|hNRD2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ACER3,-,APHC|PHCA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CNTN6,-,NB3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ICA1L,-,ALS2CR14|ALS2CR15,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ABCG2,-,ABC15|ABCP|BCRP|BCRP1|BMDP|CD338|CDw338|EST157481|GOUT1|MRX|MXR|MXR1|UAQTL1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM160B1,-,KIAA1600|bA106M7.3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FSD2,-,SPRYD1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ELTD1,-,ETL|KPG_003,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SEC22A,-,SEC22L2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CATSPER2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CDH19,-,CDH7|CDH7L2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZDHHC4,-,ZNF374,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPIB,-,CYP-S1|CYPB|HEL-S-39|OI9|SCYLP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C7orf61,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HRG,-,HPRG|HRGP|THPH11,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NUDT12,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF461,-,GIOT-1|GIOT1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MAPKAPK5,-,MAPKAP-K5|MK-5|MK5|PRAK,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM106B,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C5,-,C5D|C5a|C5b|CPAMD4|ECLZB,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM206A,-,C9orf6|CG-8,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IGSF6,-,DORA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,R3HDM1,-,R3HDM,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,METTL6,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,OSTN,-,MUSCLIN,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHD2,-,EEOC,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GAS2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IRX5,-,HMMS|IRX-2a|IRXB2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DISC1,-,C1orf136|SCZD9,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PTBP2,-,PTBLP|brPTB|nPTB,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ST6GALNAC2,-,SAITL1|SIAT7|SIAT7B|SIATL1|ST6GalNAII|STHM,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KCNH5,-,EAG2|H-EAG2|Kv10.2|hEAG2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AFMID,-,FKF|KF|KFA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CARHSP1,-,CRHSP-24|CSDC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRMT11,-,C6orf75|MDS024|TRM11|TRMT11-1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KCNT2,-,KCa4.2|SLICK|SLO2.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SIT1,-,SIT|SIT-R,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,COLEC10,-,CLL1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STK33,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM49A,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NOL4,-,CT125|NOLP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TBC1D12,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARHGDIA,-,GDIA1|HEL-S-47e|NPHS8|RHOGDI|RHOGDI-1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,XYLB,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANKRD28,-,PITK|PPP1R65,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZSWIM2,-,MEX|ZZZ2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GPR160,-,GPCR1|GPCR150,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IL17RD,-,HH18|IL-17RD|IL17RLM|SEF,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF175,-,OTK18,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PHACTR4,-,PPP1R124,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NEK7,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IFT74,-,CCDC2|CMG-1|CMG1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HIST3H2BB,-,H2Bb,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FXYD2,-,ATP1G1|HOMG2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IFI27,-,FAM14D|ISG12|ISG12A|P27,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CTDSPL,-,C3orf8|HYA22|PSR1|RBSP3|SCP3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MTF2,-,M96|PCL2|TDRD19A|dJ976O13.2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERBB2IP,-,ERBIN|HEL-S-78|LAP2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FGB,-,HEL-S-78p,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AMPD3,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SUGP2,-,SFRS14,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM19A2,-,TAFA-2|TAFA2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PALMD,-,C1orf11|PALML,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC83,-,CT148,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,WDR31,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAP,-,DPPIV|FAPA|SIMP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AP4E1,-,CPSQ4|SPG51,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RBL2,-,P130|Rb2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SYPL1,-,H-SP1|SYPL,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AFF2,-,FMR2|FMR2P|FRAXE|MRX2|OX19,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TM4SF1,-,H-L6|L6|M3S1|TAAL6,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MAMDC4,-,AEGP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MS4A10,-,CD20L7|MS4A9,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SCN9A,-,ETHA|FEB3B|GEFSP7|HSAN2D|NE-NA|NENA|Nav1.7|PN1|SFNP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLCO1B1,-,HBLRR|LST-1|LST1|OATP-C|OATP1B1|OATP2|OATPC|SLC21A6,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ALPK2,-,HAK,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GATAD1,-,CMD2B|ODAG|RG083M05.2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLD5,-,PLDC,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHRNB3,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NPC1,-,NPC,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TDP1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RAB21,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TERF1,-,PIN2|TRBF1|TRF|TRF1|hTRF1-AS|t-TRF1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TOR2A,-,TORP1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ADAM28,-,ADAM 28|ADAM23|MDC-L|MDC-Lm|MDC-Ls|MDCL|eMDC II|eMDCII,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STX3,-,STX3A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCBL2,-,KAT3|KATIII,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ADAMTS18,-,ADAMTS21|KNO2|MMCAT,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NPPC,-,CNP|CNP2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NME8,-,CILD6|NM23-H8|SPTRX2|TXNDC3|sptrx-2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VTI1B,-,VTI1|VTI1-LIKE|VTI1L|VTI2|v-SNARE|vti1-rp1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANKHD1,-,MASK|VBARP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,APOBEC1,-,APOBEC-1|BEDP|CDAR1|HEPR,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RASSF6,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KTN1,-,CG1|KNT|MU-RMS-40.19,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GAS8,-,GAS11,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLS3,-,BMND18|T-plastin,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZC3HAV1,-,ARTD13|FLB6421|PARP13|ZAP|ZC3H2|ZC3HDC2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MMP1,-,CLG|CLGN,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRPC4AP,-,C20orf188|PPP1R158|TRRP4AP|TRUSS,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GOLGA4,-,CRPF46|GCP2|GOLG|MU-RMS-40.18|p230,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TTC13,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TM2D3,-,BLP2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BCL2L11,-,BAM|BIM|BOD,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ELAVL4,-,HUD|PNEM,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PRELID2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MANSC4,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SEMA6A,-,HT018|SEMA|SEMA6A1|SEMAQ|VIA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLBD1,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IGSF10,-,CMF608,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NLRP9,-,CLR19.1|NALP9|NOD6|PAN12,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATP6V0A1,-,ATP6N1|ATP6N1A|Stv1|VPP1|Vph1|a1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PI4K2A,-,PI4KII|PIK42A,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,APOBEC3A,-,A3A|ARP3|PHRBN|bK150C2.1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FGF8,-,AIGF|FGF-8|HBGF-8|HH6|KAL6,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GPRC5B,-,RAIG-2|RAIG2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXO7,-,FBX|FBX07|FBX7|PARK15|PKPS,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SEMA3E,-,M-SEMAH|M-SemaK|SEMAH|coll-5,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC27A2,-,ACSVL1|FACVL1|FATP2|HsT17226|VLACS|VLCS|hFACVL1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC2A2,-,GLUT2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UTS2,-,PRO1068|U-II|UCN2|UII,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC31A2,-,COPT2|CTR2|hCTR2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMX3,-,PDIA13|TXNDC10,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,WLS,-,C1orf139|EVI|GPR177|MRP|mig-14,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SUFU,-,PRO1280|SUFUH|SUFUXL,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SYNE3,-,C14orf49|NET53|Nesp3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GLG1,-,CFR-1|ESL-1|MG-160|MG160,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UBE2B,-,E2-17kDa|HHR6B|HR6B|RAD6B|UBC2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,XPO4,-,exp4,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHRNA1,-,ACHRA|ACHRD|CHRNA|CMS2A|FCCMS|SCCMS,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARFIP2,-,POR1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRAF5,-,MGC:39780|RNF84,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GCC2,-,GCC185|RANBP2L4|REN53,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FUZ,-,FY|NTD,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ITLN2,-,HL-2|HL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DDHD2,-,SAMWD1|SPG54|iPLA(1)gamma,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRRC16B,-,C14orf121|CARMIL3|crml-1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ADK,-,AK,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PAK2,-,PAK65|PAKgamma,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SERPINB7,-,MEGSIN|PPKN|TP55,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRRK2,-,AURA17|DARDARIN|PARK8|RIPK7|ROCO2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DSE,-,DSEP|DSEPI|EDSMC2|SART-2|SART2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF451,-,COASTER|dJ417I1.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IQUB,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRRC42,-,dJ167A19.4,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NOA1,-,C4orf14|MTG3|hAtNOS1|hNOA1|mAtNOS1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MCHR2,-,GPR145|GPRv17|MCH-2R|MCH-R2|MCH2|MCH2R|MCHR-2|SLT,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C6orf211,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CAPN2,-,CANP2|CANPL2|CANPml|mCANP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PRRX2,-,PMX2|PRX2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TOMM20L,-,UNQ9438,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TTBK2,-,SCA11|TTBK,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SPATA6,-,HASH|SRF-1|SRF1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GNPAT,-,DAP-AT|DAPAT|DHAPAT,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GBE1,-,APBD|GBE|GSD4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ACAD8,-,ACAD-8|ARC42,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PIK3C2A,-,CPK|PI3-K-C2(ALPHA)|PI3-K-C2A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RSRC2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CNGB1,-,CNCG2|CNCG3L|CNCG4|CNG4|CNGB1B|GAR1|GARP|GARP2|RCNC2|RCNCb|RCNCbeta|RP45,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SCLT1,-,CAP-1A|CAP1A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AKR1C3,-,DD3|DDX|HA1753|HAKRB|HAKRe|HSD17B5|PGFS|hluPGFS,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SUMO3,-,SMT3A|SMT3H1|SUMO-3|Smt3B,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PRKAA2,-,AMPK|AMPK2|AMPKa2|PRKAA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RBMS1,-,C2orf12|HCC-4|MSSP|MSSP-1|MSSP-2|MSSP-3|SCR2|YC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHMP4C,-,SNF7-3|Shax3|VPS32C,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZMYND15,-,SPGF14,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERLEC1,-,C2orf30|CIM|CL24936|CL25084|HEL117|XTP3-B|XTP3TPB,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CDK11A,-,CDC2L2|CDC2L3|CDK11-p110|CDK11-p46|CDK11-p58|PITSLRE|p58GTA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANO10,-,SCAR10|TMEM16K,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RANBP10,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ST5,-,DENND2B|HTS1|p126,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF165,-,CT53|LD65|ZSCAN7,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC41A2,-,SLC41A1-L1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DZANK1,-,ANKRD64|C20orf12|C20orf84|bA189K21.1|bA189K21.8|dJ568F9.2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HNRNPUL2,-,HNRPUL2|SAF-A2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DGKH,-,DGKeta,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC8A1,-,NCX1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC7,-,BioT2-A|BioT2-B|BioT2-C|C10orf68,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,XRRA1,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TEAD2,-,ETF|TEAD-2|TEF-4|TEF4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C12orf75,-,AGD3|OCC-1|OCC1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,REEP3,-,C10orf74,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NUMB,-,C14orf41|S171|c14_5527,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MINPP1,-,HIPER1|MINPP2|MIPP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ABCB5,-,ABCB5alpha|ABCB5beta|EST422562,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLD1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HGF,-,DFNB39|F-TCF|HGFB|HPTA|SF,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VKORC1,-,EDTP308|IMAGE3455200|MST134|MST576|VKCFD2|VKOR,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TCTE3,-,TCTEX1D3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KRT20,-,CD20|CK-20|CK20|K20|KRT21,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VPS33B,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SPAG1,-,CILD28|CT140|HSD-3.8|SP75|TPIS,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC38A1,-,ATA1|NAT2|SAT1|SNAT1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,METTL20,-,C12orf72,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SOAT1,-,ACACT|ACAT|ACAT-1|ACAT1|SOAT|STAT,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SYCE1L,-,MRP2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KDM5B,-,CT31|JARID1B|PLU-1|PLU1|PPP1R98|PUT1|RBBP2H1A,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RAD9B,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SHF,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AMOT,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DQX1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EXD2,-,C14orf114|EXDL2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IST1,-,OLC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CEP41,-,JBTS15|TSGA14,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRIM69,-,HSD-34|HSD34|RNF36|Trif,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TTC3,-,DCRR1|RNF105|TPRDIII,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GLT8D2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ADCYAP1R1,-,PAC1|PAC1R|PACAPR|PACAPRI,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANKRD13A,-,ANKRD13|NY-REN-25,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SSX2IP,-,ADIP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CLMP,-,ACAM|ASAM|CSBM|CSBS,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RNF130,-,G1RZFP|GOLIATH|GP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM116,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC35G2,-,TMEM22,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPP2R1B,-,PP2A-Abeta|PR65B,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FGF1,-,AFGF|ECGF|ECGF-beta|ECGFA|ECGFB|FGF-1|FGF-alpha|FGFA|GLIO703|HBGF-1|HBGF1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GRIN1,-,GluN1|MRD8|NMD-R1|NMDA1|NMDAR1|NR1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CLPX,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RDX,-,DFNB24,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RABGAP1L,-,HHL|TBC1D18,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMTC1,-,OLF|TMTC1A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PIGF,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C9orf84,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,POLB,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TDRD10,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXO4,-,FBX4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,POC5,-,C5orf37,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC132,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC30A7,-,ZNT7|ZnT-7|ZnTL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VWA3A,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,N6AMT2,-,ESP13,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLIRP,-,C14orf156|DC50|PD04872,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ERI2,-,EXOD1|ZGRF5,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LGR5,-,FEX|GPR49|GPR67|GRP49|HG38,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PXDNL,-,PMR1|PRM1|VPO2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SWT1,-,C1orf26|HsSwt1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BBS5,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NDFIP1,-,N4WBP5,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UBXN1,-,2B28|SAKS1|UBXD10,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AHSG,-,A2HS|AHS|FETUA|HSGA,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TSC22D2,-,TILZ4a|TILZ4b|TILZ4c,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TBC1D5,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KLRF1,-,CLEC5C|NKp80,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GCNT4,-,C2GNT3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DGKE,-,DAGK5|DAGK6|DGK|NPHS7,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LAMA2,-,LAMM,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FGD6,-,ZFYVE24,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CYP24A1,-,CP24|CYP24|HCAI|P450-CC24,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CSNK2A2,-,CK2A2|CSNK2A1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM241,-,C18orf45|hVVT,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC6A3,-,DAT|DAT1|PKDYS,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SOAT2,-,ACACT2|ACAT2|ARGP2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NEBL,-,LASP2|LNEBL,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PRDX6,-,1-Cys|AOP2|HEL-S-128m|NSGPx|PRX|aiPLA2|p29,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,YWHAH,-,YWHA1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DLG1,-,DLGH1|SAP-97|SAP97|dJ1061C18.1.1|hdlg,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANKRD40,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPIL6,-,PPIase|RSPH12|bA425D10.6|dJ919F19.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DRAM2,-,PRO180|TMEM77|WWFQ154,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DHX29,-,DDX29,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CASP5,-,ICE(rel)III|ICEREL-III|ICH-3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GNPNAT1,-,GNPNAT|Gpnat1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC22A25,-,HIMTP|UST6,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC22A2,-,OCT2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,KIAA1377,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RALGPS2,-,dJ595C2.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TPM3,-,CAPM1|CFTD|HEL-189|HEL-S-82p|NEM1|OK/SW-cl.5|TM-5|TM3|TM30|TM30nm|TM5|TPMsk3|TRK|hscp30,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZHX3,-,TIX1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZC3H14,-,MSUT-2|NY-REN-37|SUT2|UKp68,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SNX24,-,PRO1284,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AKAP2,-,AKAP-2|AKAPKL|PRKA2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FLG,-,ATOD2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,WDYHV1,-,C8orf32,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SCNN1G,-,BESC3|ENaCg|ENaCgamma|PHA1|SCNEG,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PDZD9,-,C16orf65,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HIVEP1,-,CIRIP|CRYBP1|GAAP|MBP-1|PRDII-BF1|Schnurri-1|ZAS1|ZNF40|ZNF40A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MYH1,-,HEL71|MYHSA1|MYHa|MyHC-2X/D|MyHC-2x,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HHATL,-,C3orf3|GUP1|MBOAT3|MSTP002|OACT3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SARDH,-,BPR-2|DMGDHL1|SAR|SARD|SDH,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC25A12,-,AGC1|ARALAR,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TNFAIP3,-,A20|OTUD7C|TNFA1P2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRIP11,-,ACG1A|CEV14|GMAP-210|TRIP-11|TRIP230,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PADI2,-,PAD-H19|PAD2|PDI2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DNAAF1,-,CILD13|LRRC50|ODA7,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ELMOD3,-,DFNB88|LST3|RBED1|RBM29,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IL13RA1,-,CD213A1|IL-13Ra|NR4,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PLCB4,-,ARCND2|PI-PLC,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GRIA4,-,GLUR4|GLUR4C|GLURD|GluA4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CD3D,-,CD3-DELTA|IMD19|T3D,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IFI16,-,IFNGIP1|PYHIN2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SYT14,-,SCAR11|sytXIV,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ODC1,-,ODC,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PCDH18,-,PCDH68L,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DENND5B,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MAPK8,-,JNK|JNK-46|JNK1|JNK1A2|JNK21B1/2|PRKM8|SAPK1|SAPK1c,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATP8B1,-,ATPIC|BRIC|FIC1|ICP1|PFIC|PFIC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STOM,-,BND7|EPB7|EPB72,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CD80,-,B7|B7-1|B7.1|BB1|CD28LG|CD28LG1|LAB7,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LYPD6B,-,CT116|LYPD7,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SAMD9L,-,C7orf6|DRIF2|UEF1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SHC3,-,N-Shc|NSHC|RAI|SHCC,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RBM20,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TCF4,-,E2-2|ITF-2|ITF2|PTHS|SEF-2|SEF2|SEF2-1|SEF2-1A|SEF2-1B|SEF2-1D|TCF-4|bHLHb19,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HOOK1,-,HK1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CA11,-,CARPX1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SYNC,-,SYNC1|SYNCOILIN,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PTPN21,-,PTPD1|PTPRL10,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DENND4C,-,C9orf55|C9orf55B|bA513M16.3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AEBP2,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRRC1,-,LANO|dJ523E19.1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PDZRN3,-,LNX3|SEMACAP3|SEMCAP3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EFR3B,-,KIAA0953,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HOGA1,-,C10orf65|DHDPS2|DHDPSL|HP3|NPL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GRIA1,-,GLUH1|GLUR1|GLURA|GluA1|HBGR1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TBXA2R,-,BDPLT13|TXA2-R,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SUN3,-,SUNC1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF607,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CPN2,-,ACBP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SPDEF,-,PDEF|bA375E1.3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CAST,-,BS-17,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF566,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CHN1,-,ARHGAP2|CHN|DURS2|NC|RHOGAP2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLITRK3,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,COL25A1,-,AMY|CLAC|CLAC-P|CLACP,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRRC59,-,p34,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TIGD6,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,XKRX,-,XKR2|XPLAC|XRG2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VPS13B,-,CHS1|COH1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MMP8,-,CLG1|HNC|MMP-8|PMNL-CL,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PHF20L1,-,TDRD20B,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SNX10,-,OPTB8,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GRIK1,-,EAA3|EEA3|GLR5|GLUR5|GluK1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RPE65,-,BCO3|LCA2|RP20|mRPE65|rd12|sRPE65,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RNF145,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF229,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IVNS1ABP,-,FLARA3|HSPC068|KLHL39|ND1|NS-1|NS1-BP|NS1BP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF713,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PAN2,-,USP52,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MMADHC,-,C2orf25|CL25022|cblD,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARV1,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM87B,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PDE8A,-,HsT19550,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ACOXL,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ENTPD7,-,LALP1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GOLPH3L,-,GPP34R,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PP2D1,-,C3orf48,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,POLN,-,POL4P,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RXFP1,-,LGR7|RXFPR1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LUZP2,-,KFSP2566|PRO6246,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C11orf54,-,PTD012|PTOD012,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF510,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ETFA,-,EMA|GA2|MADD,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,REG3A,-,HIP|HIP/PAP|INGAP|PAP|PAP-H|PAP1|PBCGF|REG-III|REG3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HCN1,-,BCNG-1|BCNG1|EIEE24|HAC-2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPAPDC1B,-,DPPL1|HTPAP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IDE,-,INSULYSIN,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HMGA2,-,BABL|HMGI-C|HMGIC|LIPO|STQTL9,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BTN3A2,-,BT3.2|BTF4|BTN3.2|CD277,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VPS26B,-,Pep8b,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ANGPTL3,-,ANG-5|ANGPT5|ANL3|FHBL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CCDC169,-,C13orf38,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM64,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GEN1,-,Gen,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZIM3,-,ZNF657,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GTF2A1L,-,ALF,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,COMMD1,-,C2orf5|MURR1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATP11C,-,ATPIG|ATPIQ,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FYTTD1,-,UIF,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NOSTRIN,-,DaIP2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CXorf58,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MCOLN2,-,TRP-ML2|TRPML2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,THBS1,-,THBS|THBS-1|TSP|TSP-1|TSP1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CLOCK,-,KAT13D|bHLHe8,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MPZ,-,CHM|CMT1|CMT1B|CMT2I|CMT2J|CMT4E|CMTDI3|CMTDID|DSS|HMSNIB|MPP|P0,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MTRF1,-,MRF1|MTTRF1|RF1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARHGAP26,-,GRAF|GRAF1|OPHN1L|OPHN1L1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF225,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NPAS2,-,MOP4|PASD4|bHLHe9,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRIM36,-,HAPRIN|RBCC728|RNF98,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NUDT13,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RPS6KA2,-,HU-2|MAPKAPK1C|RSK|RSK3|S6K-alpha|S6K-alpha2|p90-RSK3|pp90RSK3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXO16,-,FBX16,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPP1R14C,-,CPI17-like|KEPI|NY-BR-81,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TLL2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LEPROT,-,LEPR|OB-RGRP|OBRGRP|VPS55,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LY6G5B,-,C6orf19|G5b,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM87A,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PDE10A,-,HSPDE10A,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM14B,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EVI5,-,NB4S,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ARF5,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SEC61A2,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RGS7,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FBXO3,-,FBA|FBX3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UBQLN1,-,DA41|DSK2|PLIC-1|UBQN|XDRP1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DSPP,-,DFNA39|DGI1|DMP3|DPP|DSP|DTDP2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ELOVL3,-,CIG-30|CIG30,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PPP2R5A,-,B56A|PR61A,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HERC6,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HIST1H2AH,-,H2A/S|H2AFALii|H2AH|dJ86C11.1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF200,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DCK,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CASQ1,-,CASQ|PDIB1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,EAF2,-,BM040|TRAITS|U19,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,INSL3,-,RLF|RLNL|ley-I-L,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM216B,-,C13orf30,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NPHP3,-,CFAP31|MKS7|NPH3|RHPD|RHPD1|SLSN3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ACCSL,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,COL11A1,-,CO11A1|COLL6|STL2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CYP2J2,-,CPJ2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C2orf78,-,COG5373|hCG1989538,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TCTN3,-,C10orf61|JBTS18|OFD4|TECT3,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RGS8,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HTR3D,-,5HT3D,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC9A8,-,NHE-8|NHE8,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,HRH2,-,H2R,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GPR107,-,GCDRP|LUSTR1|bA138E2.2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BICC1,-,BICC|CYSRD,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ETV5,-,ERM,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FAM20C,-,DMP-4|DMP4|GEF-CK|RNS,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PXDC1,-,C6orf145,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,VRK2,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CRYZ,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RECQL,-,RECQL1|RecQ1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC52A3,-,BVVLS|BVVLS1|C20orf54|RFT2|RFVT3|bA371L19.1|hRFT2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,JAK2,-,JTK10|THCYT3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PYGO1,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PAK1,-,PAKalpha,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CEP78,-,C9orf81|IP63,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ADAM10,-,AD10|AD18|CD156c|HsT18717|MADM|RAK|kuz,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TOM1L1,-,OK/KNS-CL.3|SRCASM,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATAD3C,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC25A13,-,ARALAR2|CITRIN|CTLN2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CASP6,-,MCH2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IBTK,-,BTBD26|BTKI,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,UBR7,-,C14orf130,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MCOLN3,-,TRP-ML3|TRPML3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CTSO,-,CTSO1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GAS2L2,-,GAR17,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,C11orf1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RNF121,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AKAP7,-,AKAP15|AKAP18,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CACNG1,-,CACNLG,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ZNF776,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,FABP12,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ATP5G1,-,ATP5A|ATP5G,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BAZ2B,-,WALp4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SAMD7,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,NCOA1,-,F-SRC-1|KAT13A|RIP160|SRC1|bHLHe42|bHLHe74,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,GMNC,-,GEMC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,STXBP5L,-,LLGL4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC35B4,-,YEA|YEA4,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ORAI1,-,CRACM1|IMD9|ORAT1|TAM2|TMEM142A,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TSPAN6,-,T245|TM4SF6|TSPAN-6,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ELMO1,-,CED-12|CED12|ELMO-1,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM248,-,C7orf42,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMCO5A,-,TMCO5,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TIGD2,-,HEL106,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PCOLCE2,-,PCPE2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LBP,-,BPIFD2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PAM,-,PAL|PHM,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CMTM3,-,BNAS2|CKLFSF3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MASP1,-,3MC1|CRARF|CRARF1|MAP1|MASP|MASP3|MAp44|PRSS5|RaRF,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CTSH,-,ACC-4|ACC-5|CPSB|minichain,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,SLC7A13,-,AGT-1|AGT1|XAT2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MAGED2,-,11B6|BCG-1|BCG1|HCA10|MAGE-D2,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MID2,-,FXY2|MRX101|RNF60|TRIM1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,PTH,-,PTH1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,BPIFA3,-,C20orf71|SPLUNC3,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CLEC1A,-,CLEC-1|CLEC1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DCP1B,-,DCP1|hDcp1b,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TMEM136,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,DLAT,-,DLTA|PDC-E2|PDCE2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MFI2,-,CD228|MAP97|MTF1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,APLNR,-,AGTRL1|APJ|APJR|HG11,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RAP1GDS1,-,GDS1|SmgGDS,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,RAB3GAP2,-,RAB3-GAP150|RAB3GAP150|SPG69|WARBM2|p150,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CXorf56,-,-,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TRPC6,-,FSGS2|TRP6,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TET3,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,MSH4,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,AXDND1,-,C1orf125,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,ITFG1,-,TIP,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,LRRD1,-,-,T47D,Growth abnormality|viability,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,CDC14A,-,cdc14|hCDC14,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,IRX2,-,IRXA2,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
CSK,TBX19,-,TBS19|TPIT|dJ747L4.1,T47D,viability|Growth abnormality,"CRISPR GI screen|Cell Line:T47D|Experimental Setup: Timecourse, negative selection, viability|GIST: A-phenotypic negative genetic interaction|Library: Geckov2|Significance Threshold: FDR<0.05",synthetic lethality
ATRX,PLN,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CMD1P|CMH18|PLB,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RRM2,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,R2|RR2|RR2M,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,STX18,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,Ufe1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,PKMYT1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,MYT1|PPP1R126,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,SMC1A,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CDLS2|DXS423E|SB1.8|SMC1|SMC1L1|SMC1alpha|SMCB,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,CDCA8,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,BOR|BOREALIN|DasraB|MESRGP,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,WDR33,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,NET14|WDC146,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,WEE1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,WEE1A|WEE1hu,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,EIF2S3,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,EIF2|EIF2G|EIF2gamma|eIF-2gA,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,IARS2,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,ILERS,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,HSPA9,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CRP40|CSA|GRP-75|GRP75|HEL-S-124m|HSPA9B|MOT|MOT2|MTHSP75|PBP74,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,EIF3B,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,EIF3-ETA|EIF3-P110|EIF3-P116|EIF3S9|PRT1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RABGGTA,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,PTAR3,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,POMK,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,MDDGA12|MDDGC12|SGK196,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,VCP,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,ALS14|HEL-220|HEL-S-70|IBMPFD|IBMPFD1|TERA|p97,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TUBA1B,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,K-ALPHA-1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,CABIN1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CAIN|PPP3IN,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,ASF1A,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CGI-98|CIA|HSPC146,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RNMT,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,MET|RG7MT1|hCMT1c,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,MCM4,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CDC21|CDC54|NKCD|NKGCD|P1-CDC21|hCdc21,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,NUDCD3,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,NudCL,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,SKA3,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,C13orf3|RAMA1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,ATP6V1B2,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,ATP6B1B2|ATP6B2|HO57|VATB|VPP3|Vma2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RPL7A,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,L7A|SURF3|TRUP,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RBM39,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CAPER|CAPERalpha|FSAP59|HCC1|RNPC2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TIPIN,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,-,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,PSMA2,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,HC3|MU|PMSA2|PSC2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,CSTF1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CstF-50|CstFp50,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,DYNLRB1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,BITH|BLP|DNCL2A|DNLC2A|ROBLD1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TRA2B,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,Htra2-beta|PPP1R156|SFRS10|SRFS10|TRA2-BETA|TRAN2B,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,HAT1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,KAT1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TOPBP1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,TOP2BP1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,DDX46,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,PRPF5|Prp5,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RBM27,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,ARRS1|Psc1|ZC3H18,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,CENPN,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,BM039|C16orf60|CENP-N|ICEN32,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,PSMG4,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,C6orf86|PAC4|bA506K6.2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,DBR1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,-,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,XKRX,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,XKR2|XPLAC|XRG2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,SMC5,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,SMC5L1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,DGCR14,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,DGCR13|DGS-H|DGS-I|DGSH|DGSI|ES2|Es2el,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,SMC6,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,SMC-6|SMC6L1|hSMC6,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,BTF3L4,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,-,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,SMN1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,BCD541|GEMIN1|SMA|SMA1|SMA2|SMA3|SMA4|SMA@|SMN|SMNT|T-BCD541|TDRD16A,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,SMARCD1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,BAF60A|CRACD1|Rsc6p,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,C6orf15,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,STG,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TRAPPC4,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,HSPC172|PTD009|SBDN|SYNBINDIN|TRS23,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,IL1R2,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CD121b|CDw121b|IL-1R-2|IL-1RT-2|IL-1RT2|IL1R2c|IL1RB,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,PDZD7,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,PDZK7,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,UBE2J1,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,HSPC153|HSPC205|HSU93243|NCUBE-1|NCUBE1|UBC6|Ubc6p,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,C14orf166,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CGI99|CLE|CLE7|LCRP369|RLLM1,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,CDK12,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CRK7|CRKR|CRKRS,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TUBB,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CDCBM6|M40|OK/SW-cl.56|TUBB1|TUBB5,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,RGPD6,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,RGP6|RGPD7|RanBP2L1|RanBP2L2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,COASY,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,DPCK|NBIA6|NBP|PPAT|UKR1|pOV-2,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,FNTB,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,FPTB,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,TUBGCP6,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,GCP-6|GCP6|MCCRP|MCPHCR,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,ZAP70,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,SRK|STCD|STD|TZK|ZAP-70,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
ATRX,CSTF3,ATR2|JMS|MRXHF1|RAD54|RAD54L|SFM1|SHS|XH2|XNP|ZNF-HX,CSTF-77,PLC-PRF-5 (Hepatoma Cell Line),Growth abnormality,"CRISPR GI screen|Cell Line: PLC-PRF-5 (Hepatoma Cell Line)|Experimental Setup: Timecourse|GIST: A-phenotypic negative genetic interaction|Library: GeckoV2|Significance Threshold: Authors looked for genes which We then searched for genes targeted by the sgRNAs that were represented at nearly the same level at T0 as at T21 in ATRX WT cells, but depleted in ATRX KO cells at T21 compared with T0. Under these stringent criteria, we identified 58 genes, which were essential for viability in ATRX KO cells but nonessential for ATRX WT cells, as potential synthetic lethal partners for ATRX and signified genes that met this criteria in a hit list in the supp file",synthetic lethality
